Mosaic ImmunoEngineering is a nanotechnology-based immunotherapy company developing therapeutics and vaccines to positively impact the lives of patients and their families.

Free
Message: Brian, If you are reading this board

Actually, I do believe that was what Pohl found perplexing. One would resonably assume, with what all PTSC had/has going for it, that the retail demand would be more than sufficient to overcome S&L's sell strategy.

You could then play the "what if" game.

What if S&L slowed their action? Well, it would just take that much longer to get rid of the warrants, which are an issue to most astute investors.

What if PTSC pushed the PR button? Well, then would be viewed as a pump and dump scheme (and it would be, with S&L doing the dumping).

Any other "what ifs" out there? Maybe Pohl being more forthright in his comment? See the first paragraph above. And keep in mind that Polh spoke those words right after it had been stated that the SP would be "volitile".

If anyone can come up with a "what if" scenario I've missed, please advise.

Some may argue that S&L could have put the brakes on at a higher base. Perhaps, but the down side would be that PTSC would be a less appealing buy considering some measure of uncertainty still looming. This, again, would have slowed the conversion process IMO, i.e., less demand = fewer opportunities for selling to convert via lower volume.

JMHO, and I KNOW nuttin'!

SGE

Share
New Message
Please login to post a reply